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BRONCHIECTASIS
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Background: The clinical efficacy of inhaled corticosteroid (ICS) treatment has not been evaluated in
bronchiectasis, despite the presence of chronic airway inflammation.
Methods: After three consecutive weekly visits, 86 patients were randomised to receive either fluticasone
500 mg twice daily (n = 43, 23F, mean (SD) age 57.7 (14.4) years) or matched placebo (n = 43, 34F,
59.2 (14.2) years) and reviewed regularly for 52 weeks in a double blind fashion.
Results: 35 and 38 patients in the fluticasone and placebo groups completed the study. Significantly more
patients on ICS than on placebo showed improvement in 24 hour sputum volume (OR 2.5, 95% CI 1.1 to
6.0, p = 0.03) but not in exacerbation frequency, forced expiratory volume in 1 second, forced vital
capacity, or sputum purulence score. Significantly more patients with Pseudomonas aeruginosa infection
receiving fluticasone showed improvement in 24 hour sputum volume (OR 13.5, 95% CI 1.8 to 100.2,
p = 0.03) and exacerbation frequency (OR 13.3, 95% CI 1.8 to 100.2, p = 0.01) than those given placebo.
Logistic regression models revealed a significantly better response in sputum volume with fluticasone
treatment than with placebo among subgroups of patients with 24 hour sputum volume,30 ml (p = 0.04),
exacerbation frequency (2/year (p = 0.04), and sputum purulence score .5 (p = 0.03).
Conclusions: ICS treatment is beneficial to patients with bronchiectasis, particularly those with
P aerurginosa infection.
B
ronchiectasis is a debilitating disease of heterogeneous
aetiology, and affected patients suffer from chronic
sputum production and recurrent exacerbations. The
three pathogenic elements in bronchiectasis—namely, airway
infection, inflammation and enzymatic activities1 2—interact
to result in progressive airway damage.3 Many patients
eventually harbour Pseudomonas aeruginosa (PA) in their
airway, which is associated with significant morbidity.4
Intense and harmful neutrophilic infiltration into the
bronchiectatic airway occurs, mediated by proinflammatory
mediators such as interleukin (IL)-1, IL-8, tumour necrosis
factor (TNF)-a, and leukotriene (LT) B4.3 Release of
neutrophil derived toxic products such as elastase and matrix
metalloproteinases is upregulated in bronchiectasis, and
these further damage the structure and functioning of the
airway mucosa by digesting airway elastin, basement
membrane collagen, and proteoglycan.5 The sputum elastase
level correlates with sputum production, lung function, and
airway cytokine expression in bronchiectasis.2
Systemic corticosteroid therapy reduces sputum production
in patients who develop bronchiectasis secondary to the
bronchiolitis obliterans syndrome,6 and improves growth and
spirometric parameters but has unacceptable side effects in
cystic fibrosis (CF).7 There have only been two controlled
studies of the use of inhaled corticosteroid (ICS) in non-CF
bronchiectasis1 8 and several in CF.9–12 These suggest that ICS
treatment improves bronchial hyperresponsiveness, respira-
tory symptoms, and spirometric parameters in CF.10–12
Treatment with inhaled beclomethasone for 6 weeks reduced
24 hour sputum production by 18% and resulted in marginal
improvements in peak expiratory flow rate (PEFR), forced
expiratory volume in 1 second (FEV1), and cough in 20
patients with non-CF bronchiectasis.8 We have reported that
administration of inhaled fluticasone for 8 weeks improved
sputum leucocyte density and proinflammatory cytokines in
bronchiectasis.1 Although ICS treatment might therefore
reduce leucocyte trafficking into the bronchiectatic airways
and alleviate further damage,2 its efficacy in bronchiectasis
has not been examined. We have undertaken a randomised,
double blind, placebo controlled study to evaluate the clinical
efficacy of 12 months of treatment with inhaled fluticasone
in patients with stable bronchiectasis.
METHODS
Patient selection
Patients with HRCT proven bronchiectasis were recruited
with written informed consent. Inclusion criteria included
absence of asthma or other unstable systemic diseases1 13 and
presence of stable bronchiectasis (,20% alteration in 24 hour
sputum volume, FEV1 and forced vital capacity (FVC) with
no deterioration in respiratory symptoms at baseline visits).1
Exclusion criteria included unreliable clinic attendance,
known adverse or allergic reactions to fluticasone or
quinolones, and regular usage of ICS. Each patient was
confirmed to be in a stable condition by three consecutive
weekly assessments before randomisation (block of 4) to
receive either fluticasone (500 mg twice daily) or placebo
administered with the Accuhaler device. Evaluation of
clinical and laboratory parameters was performed by the
same team at 22, 21, 0, 4, 12, 24, 36, 48, and 52 weeks. The
study protocol was approved by the institutional ethics
committee.
Clinical assessment
The number of bronchiectatic lung lobes (including lingula)
was determined from an HRCT scan performed within the
previous 12 months for each patient.14 The number of
exacerbations occurring in the preceding 12 months was
determined from the history and review of clinical charts. An
exacerbation was defined as persistent (>24 hour) deteriora-
tion in at least three respiratory symptoms (including cough,
dyspnoea, haemoptysis, increased sputum purulence or
volume, and chest pain), with or without fever (>37.5 C˚),
radiographic deterioration, systemic disturbances, or deter-
ioration in chest signs.1 Lung function was measured with a
SensorMedics 2200 (SensorMedics, Yorba Linda, USA)
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package. A structured respiratory history and physical
examination was undertaken at each visit.
Sputum examination
The volume of a 24 hour sputum collection (to the nearest
ml) was determined as the mean of a 3 day collection.1 Fresh
sputum was obtained from each patient after chest physio-
therapy. Sputum purulence was scored as 0, 1, 2, 3, 4, 5, 6, 7
or 8 (absence of, completely transparent, almost transparent,
translucent but colourless, opaque and milky white, grey,
pale green, moderately green, and dark green sputum,
respectively) by the same experienced technician.4 Standard
microbiological procedures were employed, using enriched
and selective media, to identify all sputum bacteria.1 4
Treatment protocol for exacerbations
Each patient telephoned the principal investigator (KWT)
when there was deterioration in respiratory symptoms and
was assessed within 24 hours to confirm the presence of an
exacerbation. Oral levofloxacin (300 mg twice daily for
10 days) was prescribed empirically for all exacerbations.
Patients were telephoned to ensure satisfactory progress.
When clinical deterioration occurred, the patient would
either be admitted to hospital or followed up as deemed
necessary. Compliance was enforced by weekly telephone
calls and diary cards, and monitored by checking the number
of remaining doses displayed on the Accuhalers.
Assessment of response to treatment
A treatment response was attributed to each of the primary
outcome (24 hour sputum volume, cumulative exacerbation
frequency) and secondary outcome (sputum purulence score,
FEV1 %, and FVC %) parameters by comparing the data
following treatment with the baseline data for each patient.
Improvement or deterioration in each of the outcome
parameters was attributed when a parameter showed a
change of .20% change in either direction after treatment.
No change was attributed to a parameter when the change
after treatment was(20% compared with the baseline level.
In patients withdrawn from the study the clinical response
was evaluated by comparing baseline data with those
obtained at the last visit for intent-to-treat analysis.
Statistical methods and data analysis
The objective of this trial was to evaluate the clinical efficacy
of ICS treatment in bronchiectasis. The primary outcome
variables of interest were 24 hour sputum volume and
exacerbation frequency. There are no published data on the
effects of ICS treatment on exacerbation frequency. Our
follow up on 82 stable patients with bronchiectasis showed
that 8% of patients would experience a spontaneous
improvement in 24 hour sputum volume (unpublished data),
defined as .20% reduction in sputum volume, compared
with baseline. We anticipated that treatment with fluticasone
would increase the proportion of patients who improved to
about 30%, and power calculation showed that a sample size
of 40 per group would have 80% power at a 5% alpha level.15
Data are expressed as mean (SD) unless otherwise stated.
A logistic regression model was constructed on the subgroup
of patients with a 24 hour sputum volume of ,30 ml using
sputum volume response as the dependent variable and
exacerbation frequency, sputum purulence, sputum PA
status, FEV1 and FVC as independent variables. Likewise,
regression models were constructed on each of the subgroups
of patients with exacerbation frequency of (2/year and a
sputum purulence score of .5 using the aforementioned
parameters as independent variables where appropriate.
Regression analysis was not undertaken for PA status in
view of the small sample size.
Categorical variables, including clinical response in the
primary and secondary outcome parameters, were compared
between treatment groups using x2 or Fisher’s exact tests
which also provided odds ratios (OR) and 95% confidence
intervals (CI). Continuous data were compared using the t
test or Wilcoxon rank sum test where appropriate. Unless
otherwise stated, only intent-to-treat analysis was performed
for outcome parameters for all the randomised patients. The
analysis was performed using SPSS Version 10.0 (SPSS Inc,
Chicago, IL, USA). A p value of ,0.05 was considered
statistically significant.
RESULTS
Patient demography and clinical details
Between September 1998 and May 1999, 86 patients were
recruited to the study (table 1). There was no significant
difference in sex distribution, age, age at onset of symptoms,
smoking history, past medical history, current medications,
sputum pathogens, or the number of bronchiectatic lung
segments between the two groups (p.0.05). The aetiology of
bronchiectasis did not differ between the two groups
(p.0.05) and was as follows: idiopathic (fluticasone n=
35, placebo n=34), post-tuberculous (n=6, n=6), post-
pneumonic (n=0, n=2), primary ciliary dyskinesia (n=2,
n=0), and IgG deficiency (n=0, n=1). Sore throat was the
only reported adverse reaction and affected seven (16.3%)
and two (4.7%) patients in the fluticasone and placebo
groups, respectively (p=0.16). Compliance (total dose taken
by each patient at the end of treatment) was 90.6 (16.5)% for
the fluticasone group and 91.2 (12.4)% for the placebo group
(p=0.86).
Patient withdrawals
The numbers of patients who completed the 52 week
assessment in the fluticasone and placebo groups were 35
and 38, respectively (fig 1, p=0.37). In the fluticasone group
eight patients were withdrawn for the following reasons:
Table 1 Clinical characteristics of patients in the
fluticasone and placebo groups at baseline
Fluticasone
(n = 43, 23F)
Placebo
(n = 43, 34F)
Age (years) 57.7 (14.4) 59.2 (14.2)
Age at onset of symptoms (years) 41.8 (18.8) 40.8 (18.5)
Smoking history
Never 33 36
Ex 8 7
Current 2 0
Past medical history
Nil else 26 25
Hypertension 5 4
Hypothyroidism 0 2
Pulmonary TB 3 0
Ischaemic heart disease 2 4
Peptic ulcer disease 2 2
Others 8 7
Current medications
None 17 11
Inhaled bronchodilators 11 19
Antihypertensives 5 5
Theophylline or oral b2 agonist 7 7
Others 12 8
Sputum pathogen
Commensals 25 27
P aeruginosa 12 11
H influenzae 6 5
No. of bronchiectatic lung
segments
3.0 (1.6) 2.8 (1.6)
Data shown are mean (SD).
*No significant difference between fluticasone and placebo groups
(p.0.05).
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poor compliance (,50% of prescribed doses taken, n=1, M,
4 weeks), myocardial infarction (n=1, M, 6 weeks), preg-
nancy (n=1, F, 36 weeks), reluctance to continue (n=2, 2F,
4 and 22 weeks), death from road traffic accident (n=1, F,
52 weeks), severe haemoptysis (n=1, F, 50 weeks), and
severe back pain due to collapse of fourth lumbar spine
(n=1, F, 32 weeks). In the placebo group five patients were
withdrawn as follows: reluctance to continue (n=1, F,
4 weeks), poor compliance (n=2, 1M, 1F, both at 24 weeks),
development of a severe exacerbation (n=1, F, 24 weeks),
and death from myocardial infarction (n=1, M, 52 weeks).
24 hour sputum volume
Logistic regression models undertaken with treatment
modality, baseline sputum purulence score, baseline exacer-
bation frequency, sputum PA status, baseline FEV1, and
baseline FVC as covariates and response of sputum volume as
the dependent variable showed that fluticasone treatment
had a significant beneficial effect on sputum volume
compared with placebo in subgroups of patients with 24 hour
sputum volume ,30 ml (p=0.04), exacerbation frequency
(2/year (p=0.04), and sputum purulence score .5
(p=0.03; tables 2 and 3). Of the patients with baseline
24 hour sputum volume ,30 ml, 23 showed improvement
and 13 showed no improvement (nine showed deterioration,
four no change) in post-treatment 24 hour sputum volume,
which was significantly different from controls (16 showed
improvement, 24 no improvement (10 showed deterioration,
14 no change), p=0.04, OR 2.7, 95% CI 1.0 to 6.7). Thirteen
and three patients with baseline exacerbation frequency
(2/year showed improvement and no improvement (one
deterioration and two no change) in post-treatment 24 hour
sputum volume, which was significantly different from the
control group (11 improvement, 13 no improvement (three
deterioration, 10 no change), p=0.047, OR 5.1, 95% CI 1.2 to
22.7). Of the 36 patients in the fluticasone group who
had a sputum purulence score of .5, 23 and 13 showed
improvement and no improvement, respectively, in the
post-treatment 24 hour sputum volume (four showed deter-
ioration, nine no change) compared with the placebo group
(n=35) where 14 showed improvement, 21 no improvement
(10 showed deterioration, 11 no change), p=0.06, OR 2.7,
95% CI 1.0 to 6.9). However, this baseline sputum character-
istic did not predict clinical outcome in post-treatment
exacerbation frequency (p=0.19, data not shown). There
was no significant difference in the post-treatment 24 hour
sputum volume between the treatment groups (p=0.72).
Exacerbation frequency
There were 96 and 117 exacerbations in the fluticasone and
placebo groups, respectively, which were treated with
levofloxacin. Of these, four and five patients were admitted
to hospital (once each) for physiotherapy and other treat-
ment, although levofloxacin remained the only antibiotic
therapy. There was no difference in the number of patients
who showed improvement between the two treatment
groups (p=0.37), nor was there any difference between
the two groups in the exacerbation frequency after treatment
(p=0.41, tables 2 and 3).
Secondary outcome parameters and bronchiectasis
symptoms
There was no significant difference in the clinical response
for post-treatment sputum purulence or sputum purulence
scores between the treatment groups (p.0.05), nor was there
a significant difference in the number of patients showing
improvement or otherwise in FEV1 or FVC following
treatment (p=1.00 and 1.00, respectively; tables 2 and 3).
Between group comparisons revealed no significant differ-
ence in the percentage of patients with bronchiectasis
symptoms in the two treatment groups (p.0.05), except
that significantly fewer patients treated with fluticasone
complained of post-treatment cough (p=0.03; table 3).
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Figure 1 Trial profile.
Table 2 Clinical responses of primary and secondary outcome parameters compared with baseline data for 86 patients by
intent-to-treat analysis
Fluticasone group (n = 43, 23F) Placebo group (n = 43, 34F)
Clinical response after treatment Clinical response after treatment
Improvement
n (%)
Deterioration
n (%)
No change
n (%)
Improvement
n (%)
Deterioration
n (%)
No change
n (%)
Primary outcome parameters
24 hour sputum volume
(ml)*
28 (65.1) 5 (11.6) 10 (23.3) 18 (41.9) 10 (23.2) 15 (34.9)
Exacerbation frequency
(/year)
22 (51.2) 7 (16.2) 14 (32.6) 16 (37.2) 11 (25.6) 16 (37.2)
Secondary outcome parameters
Sputum purulence score 13 (30.2) 10 (23.3) 20 (46.5) 9 (20.9) 15 (34.9) 19 (44.2)
FEV1 % predicted 2 (4.7) 4 (9.3) 37 (86.0) 3 (7.0) 3 (7.0) 37 (86.0)
FVC % predicted 4 (9.3) 3 (7.0) 36 (83.7) 4 (9.3) 1 (2.3) 38 (88.4)
*p,0.05 when both treatment groups compared for the number of patients who showed improvement or otherwise (deterioration or no change) using x2 or
Fisher’s exact tests.
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Effects of Pseudomonas aeruginosa (PA) infection
At baseline PA was isolated in the sputum from 12 and 11
patients in the fluticasone and placebo groups, respectively (5
and 10 F; 54 (15.9) and 52 (12.1) years; p=0.03 and 0.76
respectively). These patients had no significant difference in
age at onset of symptoms, past medical history, current
medications, or number of lung lobes affected by bronch-
iectasis (p.0.05, data not shown). Of these, three patients
were withdrawn from each of the treatment groups before
52 weeks, as outlined above. Post-treatment exacerbation
frequency improved in 10 patients, deteriorated in one, and
remained unchanged in one patient in the fluticasone group,
which was significantly different from the placebo group
(three, six, and two, respectively; OR 13.3, 95% CI 1.8 to
100.2, p=0.01). Post-treatment 24 hour sputum volume
improved in nine patients, deteriorated in one patient, and
remained unchanged in two patients in the fluticasone
group, which was significantly different from the placebo
group (two, six and three, respectively; OR 13.5, 95% CI 1.8 to
100.2, p=0.01). Between group comparison showed no
significant difference in the continuous data in 24 hour
sputum volume, exacerbation frequency, FEV1, FVC, or
sputum purulence score between the two groups after
treatment (p.0.05, data not shown).
DISCUSSION
This is the first double blind, placebo controlled, randomised
study to evaluate the clinical efficacy of medium term ICS
treatment in bronchiectasis. Compared with placebo, ICS
treatment was associated with improvement in 24 hour
sputum volume in significantly more patients but not
exacerbation frequency, FEV1, FVC, or sputum purulence
score. Significantly more fluticasone patients with PA
infection (known to be associated with increased morbidity
in bronchiectasis) showed improvement in 24 hour sputum
volume and exacerbation frequency compared with the
placebo group. We have previously shown that a 24 hour
sputum volume of >30 ml, a purulence score of .5, and
exacerbation frequency of >3 are markers of severe
bronchiectasis.4 16 These clinically meaningful subgroups
were therefore selected for further analysis, despite the
relatively small sample size. Our data showed that predictors
for improvement in 24 hour sputum volume following
treatment with ICS include baseline 24 hour sputum volume
,30 ml, exacerbation frequency (2/year, and sputum
purulence score .5. There was a considerable placebo effect
symptomatically as both groups of patients reported improve-
ment in respiratory symptoms, perhaps due to the highly
supervised treatment protocol. As in the previous 6 week ICS
study, we also found that treatment with fluticasone for
52 weeks was associated with improvement in cough. Other
pretreatment clinical parameters such as spirometry, age, age
at onset of symptoms, and clinical symptoms did not predict
a favourable response to ICS treatment.
Despite the aforementioned improvement in clinical
response, there was no significant difference in the post-
treatment continuous data between the two treatment
groups. Our primary aim was to determine whether or not
ICS treatment would improve the response rate in bronch-
iectasis. There is a very large inter-individual variability in
24 hour sputum volume and disease activity parameters in
patients with bronchiectasis, and our study was not powered
to look at the effects of treatment on these parameters. In
addition, our study was specifically powered to evaluate the
efficacy of ICS on 24 hour sputum volume but not exacer-
bation frequency. There are no published data to permit
estimation of a sample size to evaluate the latter, although
the data from this trial could facilitate such estimation for
future studies. We are also aware of the potential problems
which could invalidate our assumptions made for sample size
calculation, such as the wide variations in sputum volume
even for a single individual. Although we did not perform
bronchial challenge testing to exclude asthma, none of our
patients showed significant reversibility in spirometric para-
meters, diurnal variation in PEFR, or typical asthma
symptoms.13 The baseline exacerbation frequency was derived
retrospectively and could not replace prospective data.
Although bronchiectasis is the final common path for a
wide spectrum of diseases, there is an identifiable aetiology
in 60–80%17 18 and intensive investigations only reveal
aetiological factors with implications for prognosis or specific
treatment in 15% of patients.18 Specific or disease modifying
treatment is not available and this is reflected by the
continued deterioration of patients with CF and non-CF
bronchiectasis. Treatment with mucolytics, methylxanthines,
hyperosmolar agents, or leukotriene receptor antagonists has
no effect on bronchiectasis.19 Although low dose erythromy-
cin treatment improves lung function and sputum produc-
tion, possibly by downregulation of epithelial glycoconjugate
release, its long term effects in bronchiectasis are unknown.20
Table 3 Primary and secondary outcomes and bronchiectasis symptoms assessed at baseline and after treatment by intent-to-
treat analysis
Fluticasone group (n = 43, 23F) Placebo group (n = 43, 34F)
p value* Mean (95% CI) differenceBaseline After treatment Baseline After treatment
Primary outcome parameters
24 hour sputum volume (ml) 10 (5–25) 5 (2–20) 10 (5–20) 5 (3–20) 0.72 21.0 (26.56 to 4.56)
Exacerbation frequency
(/year)
4 (2–5) 2 (1–4) 2 (1– 4) 2 (1–3) 0.41 0.42 (20.59 to 1.43)
Secondary outcome parameters
Sputum purulence score 6.1 (2.0) 5.7 (2.7) 6.0 (1.8) 5.5 (2.7) 0.73 20.21 (21.39 to 0.97)
FEV1 % predicted 74.1 (29.4) 74.4 (31.5) 74.4 (29.2) 74.4 (29.9) 1.00 20.02 (213.19 to 13.14)
FVC % predicted 83.1 (23.6) 83.1 (23.4) 85.0 (22.6) 85.9 (23.3) 0.58 2.81 (27.2 to 12.82)
% of patients with
Cough 76.7 60.5 93.0 81.4 0.03
Dyspnoea 16.3 2.3 23.3 4.7 1.00
Haemoptysis 39.5 9.3 51.2 4.7 0.68
Chest pain 32.6 18.6 41.9 16.3 0.78
Wheezing 39.5 23.3 46.5 20.9 0.80
Fatigue 74.4 55.8 65.1 69.8 0.18
Unless otherwise stated, data are shown as mean (SD).
*p value for between group comparison on post-treatment data.
Median (interquartile range).
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Administration of rhDNase, despite its proven efficacy in CF,
worsens exacerbation frequency and FEV1 in non-CF
bronchiectasis.21
Although patients with non-CF bronchiectasis do not
develop the ‘‘cepacia syndrome’’, infection with PA is
associated with increased sputum production, poorer lung
function, and slowing of respiratory ciliary beat in vivo.4 22
Treatment with a nebulised aminoglycoside improves sputum
PA density, lung function, and rates of hospital admission in
patients with CF23 and reduces sputum PA density and
myeloperoxidase in those with non-CF bronchiectasis.24
However, even prolonged potent antibiotic therapy cannot
eradicate PA or prevent disease progression in bronchiectasis.
Our data show that ICS treatment improves disease activity
(manifest as exacerbation frequency and 24 hour sputum
volume) in patients with PA infection. The interaction
between PA and the respiratory mucosa is poorly understood
and the role of corticosteroids in this process is even less
clear. The efficacy of ICS treatment in this subgroup of
patients suggests that corticosteroids could beneficially alter
the interaction between PA or its toxins and the bronch-
iectatic airways. The lack of effective treatment against
chronic PA infection in the airways of these patients makes it
imperative to evaluate the underlying mechanism(s).
Although asthma, COPD, and bronchiectasis are similar in
symptoms, airway inflammation, and airflow obstruction,
ICS treatment is only of proven clinical benefit in asthma
where it improves lung function and exacerbation fre-
quency.25 Such efficacy is unclear in COPD and previously
unexplored in bronchiectasis. While ICS treatment does not
halt the progression of COPD, it appears to benefit patients
with a spirometric response to ICS, FEV1 ,50%, or frequent
exacerbations.26–29 Treatment with ICS also improves respira-
tory symptoms, frequency of physician visits, and lower
airway reactivity in patients with COPD.28 29 Unlike asthma,
in which eosinophils play a major role, patients with
bronchiectasis and COPD have neutrophils as the most
prominent cells in the airways. As in COPD, our data show
that ICS treatment does not improve lung function in
bronchiectasis, even with over 90% compliance and after
52 weeks.
Glucocorticoids act by binding to a specific receptor which,
upon activation, regulates expression of proinflammatory
transcription factors such as activator protein-1, nuclear
factor of activated T cells, and nuclear factor-kB in asthma.30
The mechanism(s) for the efficacy of ICS treatment in COPD
are less clear and are unexplored in bronchiectasis, although
treatment with ICS reduces sputum output of leucocytes, IL-
1b, IL-8, and LTB4 in the latter.1 It is probable that the
improvement in sputum volume—which reflects a dampen-
ing down of disease activity—could be the result of down-
regulation of airway proinflammatory mediators. This could
lead to amelioration of leucocyte trafficking and therefore
less neutrophilic infiltration and release of toxic products into
the bronchiectatic airway.2 The lack of response in exacerba-
tion frequency with ICS treatment suggests that the
occurrence of exacerbations is more dependent on other
factors such as infection than on inflammation, at least
among patients not infected with PA. There appears therefore
to be a need to combine antimicrobial and anti-inflammatory
treatment in bronchiectasis.
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